Description of Parkinson's Disease as a Clinical Syndrome

Abstract: Parkinsonism is a clinical syndrome comprising combinations of motor problems—namely, bradykinesia, resting tremor, rigidity, flexed posture, “freezing,” and loss of postural reflexes. Parkinson's disease (PD) is the major cause of parkinsonism. PD is a slowly progressive parkinsonian syndrome that begins insidiously and usually affects one side of the body before spreading to involve the other side. Pathology shows loss of neuromelanin‐containing monoamine neurons, particularly dopamine (DA) neurons in the substantia nigra pars compacta. A pathologic hallmark is the presence of cytoplasmic eosinophilic inclusions (Lewy bodies) in monoamine neurons. The loss of DA content in the nigrostriatal neurons accounts for many of the motor symptoms, which can be ameliorated by DA replacement therapy—that is, levodopa. Most cases are sporadic, of unknown etiology; but rare cases of monogenic mutations (10 genes at present count) show that there are multiple causes for the neuronal degeneration. The pathogenesis of PD remains unknown. Clinical fluctuations and dyskinesias are frequent complications of levodopa therapy; these, as well as some motor features of PD, improve by resetting the abnormal brain physiology towards normal by surgical therapy. Nonmotor symptoms (depression, lack of motivation, passivity, and dementia) are common. As the disease progresses, even motor symptoms become intractable to therapy. No proven means of slowing progression have yet been found.

[1]  R. Moriyasu Zur pathologischen Anatomie der Paralysis agitans , 1908, Archiv für Psychiatrie und Nervenkrankheiten.

[2]  H. Ehringer,et al.  Verteilung Von Noradrenalin Und Dopamin (3-Hydroxytyramin) Im Gehirn Des Menschen Und Ihr Verhalten Bei Erkrankungen Des Extrapyramidalen Systems , 2005, Klinische Wochenschrift.

[3]  D. Hunter Coenzyme Q10 in early Parkinson disease. , 2003, Archives of neurology.

[4]  Daniel J Schaid,et al.  Survival study of Parkinson disease in Olmsted County, Minnesota. , 2003, Archives of neurology.

[5]  J. Nutt,et al.  A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. , 2002, Archives of neurology.

[6]  Joel S Perlmutter,et al.  Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. , 2002, Archives of neurology.

[7]  J. Penney,et al.  Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial , 2002, Annals of neurology.

[8]  Manjit,et al.  Neurology , 1912, NeuroImage.

[9]  Daniel J Schaid,et al.  Risk tables for parkinsonism and Parkinson's disease. , 2002, Journal of clinical epidemiology.

[10]  John Seibyl,et al.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. , 2000, JAMA.

[11]  D J Wyper,et al.  Correlation of Parkinson's disease severity and duration with 123I‐FP‐CIT SPECT striatal uptake , 2000, Movement disorders : official journal of the Movement Disorder Society.

[12]  D. Brooks,et al.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.

[13]  J W Langston,et al.  Parkinson disease in twins: an etiologic study. , 1999, JAMA.

[14]  M. Hoehn,et al.  Parkinsonism , 1998, Neurology.

[15]  O. Hornykiewicz,et al.  Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. , 1960, Parkinsonism & related disorders.

[16]  D J Brooks,et al.  An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. , 1996, Brain : a journal of neurology.

[17]  Eileen O. Smith,et al.  Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease , 1995, Annals of neurology.

[18]  T. Ishikawa,et al.  Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  M Schulzer,et al.  Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism , 1994, Annals of neurology.

[20]  R. G. Robertson,et al.  Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 1989, Neuroscience.

[21]  C. Wells Charcot the Clinician: The Tuesday Lessons , 1989 .

[22]  S. Fahn Charcot, the clinician: The Tuesday Lessons: Excerpts from nine case presentations on general neurology delivered at the Salpêtrière hospital in 1887–88 by Jean‐Martin Charcot. Translated with commentary by Christopher G. Goetz. Raven press, New York, 223, illustrated, $56.00, 1987 , 1989 .

[23]  M. Delong,et al.  Parkinsonian Symptomatology An Anatomical and Physiological Analysisa a , 1988 .

[24]  W. C. Miller,et al.  Parkinsonian symptomatology. An anatomical and physiological analysis. , 1988, Annals of the New York Academy of Sciences.

[25]  J. Penney,et al.  Striatal inhomogeneities and basal ganglia function , 1986, Movement disorders : official journal of the Movement Disorder Society.

[26]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[27]  Å. Bertler,et al.  Occurrence and distribution of catechol amines in brain. , 1959, Acta physiologica Scandinavica.

[28]  A. Carlsson,et al.  The occurrence, distribution and physiological role of catecholamines in the nervous system. , 1959, Pharmacological reviews.

[29]  R S SCHWAB,et al.  Akinesia in Parkinson's disease , 1959, Neurology.

[30]  Y. Kakimoto,et al.  Distribution of catechol compounds in human brain. , 1959, Biochimica et biophysica acta.

[31]  A. Carlsson,et al.  On the presence of 3-hydroxytyramine in brain. , 1958, Science.

[32]  A. Carlsson,et al.  3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists , 1957, Nature.

[33]  J. Greenfield,et al.  THE BRAIN-STEM LESIONS IN PARKINSONISM , 1953, Journal of neurology, neurosurgery, and psychiatry.

[34]  K. Jellinger,et al.  A Textbook of Clinical Neurology , 1928, The Indian Medical Gazette.

[35]  E. Fünfgeld,et al.  Zur pathologischen Anatomie der Paralysis agitans , 1923 .

[36]  James Hendrie Lyoyd E. BRISSAUD: LEÇONS SUR LES MALADIES NERVEUSES , 1899 .

[37]  Jhl Le??ons sur les Maladies Nerveuses , 1895 .

[38]  P. Blocq,et al.  Sur un cas de tremblement parkinsonien hémiplégique symptomatique d'une tumeur du pédoncule cérébral , 1893 .

[39]  W. Gowers,et al.  A Manual of Diseases of the Nervous System , 1887, Edinburgh Medical Journal.

[40]  P. James An Essay on the Shaking Palsy , 1817, The Medico-Chirurgical Journal and Review.